|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | C07K 16/28 | (2006.01) |
| A61K 39/395 | (2013.01) | ||
| A61K 39/395 | (2006.01) | ||
| A61K 39/39558 | (2013.01) | ||
| C07K 16/2887 | (2013.01) | ||
| A61K2039/505 | (2013.01) | ||
| C07K2317/41 | (2013.01) | ||
| A61K2039/545 | (2013.01) | ||
| A61P 35/00 | (2018.01) | ||
| C12Q 1/6886 | (2013.01) | ||
| C12Q2600/106 | (2013.01) | ||
| C12Q2600/158 | (2013.01) | ||
| A61K 45/06 | (2013.01) | ||
| G01N 33/57426 | (2013.01) | ||
| G01N2333/70596 | (2013.01) | ||
| G01N2800/52 | (2013.01) |
| (11) | Number of the document | 3665196 |
| (13) | Kind of document | T |
| (96) | European patent application number | 18755421.7 |
| Date of filing the European patent application | 2018-08-08 | |
| (97) | Date of publication of the European application | 2020-06-17 |
| (45) | Date of publication and mention of the grant of the patent | 2022-10-19 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/EP2018/071462 |
| Date | 2018-08-08 |
| (87) | Number | WO 2019/030260 |
| Date | 2019-02-14 |
| (30) | Number | Date | Country code |
| 201762542489 P | 2017-08-08 | US |
| (72) |
OESTERGAARD, Mikkel Zahle , CH
|
| (73) |
F. Hoffmann-La Roche AG ,
Grenzacherstrasse 124, 4070 Basel,
CH
NanoString Technologies, Inc. , 530 Fairview Ave North, Seattle, WA 98109, US |
| (54) | OBINUTUZUMAB TREATMENT OF A DLBCL PATIENT SUBGROUP |
| OBINUTUZUMAB TREATMENT OF A DLBCL PATIENT SUBGROUP |